Medindia4h
AbbVie Announces European Commission Approval of RINVOQ (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis
AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...
AbbVie Announces European Commission Approval of RINVOQ (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis
RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval ...
theAsianparent1h
Premature Babies Are Vulnerable, Get to Know This Retinopathy of Prematurity Disease!
Retinopathy of prematurity (ROP) adalah kelainan yang bisa menyerang mata bayi prematur. ROP lanjut dapat menyebabkan ...